Cancer pathogenesis and therapy最新文献

{"title":"Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease","authors":"Yutong Wang ,&nbsp;Qiming Xu ,&nbsp;Yuan Li ,&nbsp;Yongbin Su ,&nbsp;Ling Wang ,&nbsp;Xiaoquan Wang ,&nbsp;Jian Ge ,&nbsp;Hongmei Jing ,&nbsp;Yuxing Guo ,&nbsp;Yalin Chen ,&nbsp;Xianan Li ,&nbsp;Jun-ling Zhuang ,&nbsp;Jing Tan ,&nbsp;Xiaobo Wang ,&nbsp;Liye Zhong ,&nbsp;Jun Luo ,&nbsp;Peng Zhao ,&nbsp;Shengjin Fan ,&nbsp;Jinhai Ren ,&nbsp;Haiping Yang ,&nbsp;Li Bao","doi":"10.1016/j.cpt.2024.12.002","DOIUrl":"10.1016/j.cpt.2024.12.002","url":null,"abstract":"<div><div>This consensus on multiple myeloma-related bone diseases (MBDs) underscores the importance of a multidisciplinary approach that encompasses hematology, radiology, orthopedics, and additional specialties to tackle its intricate challenges. MBD, a prevalent and debilitating complication of multiple myeloma, leads to bone pain, fractures, and skeletal-related events (SREs), which profoundly impact patients’ quality of life. The guidelines offer a thorough framework for diagnosis, treatment, and continual assessment, emphasizing early detection and consistent monitoring using imaging techniques such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI). Treatment strategies prioritize the careful application of anti-myeloma agents, bisphosphonates, and denosumab to minimize bone loss and decrease SRE risk, complemented by surgical and radiotherapy interventions for structural or pain-related issues. Supportive care measures, including pain management, rehabilitation, nutritional support, and dental evaluations, play a crucial role in enhancing patient outcomes and preserving quality of life. This consensus advocates a standardized, evidence-based approach to managing MBD, ensuring comprehensive and coordinated care for patients.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 4","pages":"Pages 280-292"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover","authors":"","doi":"10.1016/S2949-7132(25)00066-7","DOIUrl":"10.1016/S2949-7132(25)00066-7","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 4","pages":"Page OFC"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From bench to bedside: Advancements in urological oncology","authors":"Shaoxi Niu,&nbsp;Yaoguang Zhang,&nbsp;Hai Huang,&nbsp;Xin Ma","doi":"10.1016/j.cpt.2024.09.004","DOIUrl":"10.1016/j.cpt.2024.09.004","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 4","pages":"Pages 278-279"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lighting the path against cancer with academic light: Forty years of growth with the Chinese Medical Association—Celebrating the 110th anniversary of the founding of the Chinese Medical Association","authors":"Yuankai Shi","doi":"10.1016/j.cpt.2025.06.006","DOIUrl":"10.1016/j.cpt.2025.06.006","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 5","pages":"Pages 361-363"},"PeriodicalIF":2.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144911697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Nomogram for predicting the risk and prognosis of lung metastasis of four subtypes of breast cancer: A population-based study from SEER","authors":"Maryam Muhammad Akram ,&nbsp;Junaid Mehmood Malik ,&nbsp;Muhammad Ahsan","doi":"10.1016/j.cpt.2025.06.005","DOIUrl":"10.1016/j.cpt.2025.06.005","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 5","pages":"Pages 448-450"},"PeriodicalIF":2.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on the “Relationship between visceral obesity and prognosis in patients with stage IVB cervical cancer receiving radiotherapy and chemotherapy”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.cpt.2025.03.001","DOIUrl":"10.1016/j.cpt.2025.03.001","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 3","pages":"Pages 269-270"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity","authors":"Xingbin Hu ,&nbsp;Wenhao Ouyang ,&nbsp;Haizhu Chen ,&nbsp;Zhihong Liu ,&nbsp;Zijia Lai ,&nbsp;Herui Yao","doi":"10.1016/j.cpt.2024.09.006","DOIUrl":"10.1016/j.cpt.2024.09.006","url":null,"abstract":"<div><h3>Background</h3><div>Gastric cancer (GC) is a common malignancy characterized by the absence of reliable prognostic indicators and effective therapeutic targets. Claudin-9 (CLDN9) has been demonstrated to be upregulated in various cancers. However, its prognostic value, biological function, and regulatory mechanisms in GC remain unclear. Therefore, this study aimed to elucidate the role of <em>CLDN9</em> in GC progression and its underlying mechanisms.</div></div><div><h3>Methods</h3><div>We utilized consensus cluster, random survival forest, and multivariate Cox regression analyses to identify <em>CLDN9</em> in GC. Subsequently, we evaluated the mRNA and protein levels of <em>CLDN9</em> in GC using quantitative real-time polymerase chain reaction (PCR) (qRT-PCR), Western blotting (WB), and immunohistochemistry (IHC). Furthermore, the role of <em>CLDN9</em> in GC progression was investigated using a series of functional <em>in vivo</em> and <em>in vitro</em> experiments. Finally, we elucidated the molecular mechanisms of <em>CLDN9</em> using bioinformatics, molecular biology, animal models, and patient tissue specimens.</div></div><div><h3>Results</h3><div>Two GC subtypes with survival and functional differences were identified based on glycolytic metabolic genes in the Cancer Genome Atlas (TCGA)- Stomach adenocarcinoma (STAD) dataset. A prognostic risk score was calculated using seven genes to assess the overall survival (OS) in GC. Using random survival forest and multivariate Cox analyses, we identified <em>CLDN9</em> as the key gene linked to the glycolytic subtype and prognosis of GC. <em>CLDN9</em> expression was significantly upregulated in patients with GC as well as in GC cells. <em>CLDN9</em> knockdown inhibited tumor proliferation, invasion, and metastasis both <em>in vivo</em> and <em>in vitro</em>. Mechanistically, <em>CLDN9</em> was found to regulate lactate dehydrogenase A (LDHA) expression and promote glycolytic metabolism by activating the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/hypoxia-inducible factor 1-alpha (HIF1α) signaling pathway. Additionally, lactate, a glycolytic metabolite, enhanced programmed cell death ligand 1 (PD-L1) lactylation and stability, which suppressed anti-tumor immunity in CD8⁺ T cells, thereby contributing to GC progression.</div></div><div><h3>Conclusions</h3><div><em>CLDN9</em> expression is associated with GC development and progression. Mechanistically, <em>CLDN9</em> enhances the glycolysis pathway and facilitates PD-L1 lactylation through the PI3K/AKT/HIF1α signaling pathway, thereby suppressing anti-tumor immunity in CD8⁺ T cells. <em>CLDN9</em> has the potential to serve as a novel prognostic marker and therapeutic target for GC.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 3","pages":"Pages 253-266"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to “Integrative analysis of cuproptosis-related lncRNAs: Unveiling prognostic significance, immune microenvironment, and copper-induced mechanisms in prostate cancer” [Cancer Pathog Ther, 3 (2025):48–59]","authors":"Haitao Zhong ,&nbsp;Yiming Lai ,&nbsp;Wenhao Ouyang ,&nbsp;Yunfang Yu ,&nbsp;Yongxin Wu ,&nbsp;Xinxin He ,&nbsp;Lexiang Zeng ,&nbsp;Xueen Qiu ,&nbsp;Peixian Chen ,&nbsp;Lingfeng Li ,&nbsp;Jie Zhou ,&nbsp;Tianlong Luo ,&nbsp;Hai Huang","doi":"10.1016/j.cpt.2025.01.004","DOIUrl":"10.1016/j.cpt.2025.01.004","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 3","pages":"Pages 271-272"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New advances in lung cancer treatment: Efficacy, safety, and future research directions","authors":"Yintao Li,&nbsp;Jianxin Xue,&nbsp;Li Zhang","doi":"10.1016/j.cpt.2024.09.005","DOIUrl":"10.1016/j.cpt.2024.09.005","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 3","pages":"Pages 181-182"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover","authors":"","doi":"10.1016/S2949-7132(25)00038-2","DOIUrl":"10.1016/S2949-7132(25)00038-2","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 3","pages":"Page OFC"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}